Tuesday, 17 Sep 2019

You are here

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

An interesting study (OP0229) linked patients from the BSRBR (British Biologic Register) on a TNFi who also had serum samples taken to calculate drug levels (N=703). Two thirds had high drugs levels (which is very surprising to me as I suspected it would be far less than that due to non-adherence, spacing treatment when doing well, etc).

Those with a high level had more infections (Hazard Ratio 1.51; 95% CI 1.14-2.01) but the serious infections were not statistically more (HR 1.17; 95% CI 0.58-2.30).

Perhaps drug levels could help us identify if a patient could take less TNFi treatment and possibly reduce the number of infections. However, the study used serum samples collected for other reasons and then for this study performed drug levels so I wonder if many of the levels were not trough levels.

This study did not measure efficacy between the group nor durability of the groups so I can’t comment on any potential differences between the groups with respect to disease state and drug retention. It is something though to think about if we are to personalize medicine – get what you need and not more and not less. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.